검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | BA3021 |
Overview Company | Canadian Cancer Trials Group |
Overview Modality | ANTIBODY |
Overview Target | Ovarian Cancer |
Overview Indication | Ovarian Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | biomarker review, neither sub-study proceeded to second stage accrual |
PK/PD Species | NHP, Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, NHP, In vitro |
PK/PD Experiment | In vivo , BA3021 has potent and durable antitumor activity in human cancer xenograft mouse models, including patient-derived xenograft models. |
Toxicology Species | NHP, Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, NHP, In vitro |
Toxicology Major finding | CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021).. IPROC is an ongoing platform trial investigating novel immunotherapy combinations in platinum resistant high grade serous ovarian cancer. Here we report on the combination of durvalu… |
Clinical Data Tier / Score | A · 12 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | BA3021 |
Overview Company | Canadian Cancer Trials Group |
Overview Modality | ANTIBODY |
Overview Target | Ovarian Cancer |
Overview Indication | Ovarian Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | biomarker review, neither sub-study proceeded to second stage accrual |
PK/PD Species | NHP, Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, NHP, In vitro |
PK/PD Experiment | In vivo , BA3021 has potent and durable antitumor activity in human cancer xenograft mouse models, including patient-derived xenograft models. |
Toxicology Species | NHP, Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, NHP, In vitro |
Toxicology Major finding | CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021).. IPROC is an ongoing platform trial investigating novel immunotherapy combinations in platinum resistant high grade serous ovarian cancer. Here we report on the combination of durvalu… |
Clinical Data Tier / Score | A · 12 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교